WallStreetZenWallStreetZen

NASDAQ: ICCC
Immucell Corp Stock

$4.77-0.29 (-5.73%)
Updated May 31, 2023
ICCC Price
$4.77
Fair Value Price
$5.17
Market Cap
$36.95M
52 Week Low
$4.26
52 Week High
$9.61
P/E
-7.01x
P/B
1.31x
P/S
2.49x
PEG
N/A
Dividend Yield
N/A
Revenue
$16.01M
Earnings
-$5.32M
Gross Margin
30.3%
Operating Margin
-33.18%
Profit Margin
-33.2%
Debt to Equity
0.53
Operating Cash Flow
-$5M
Beta
0.18
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

ICCC Overview

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ICCC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ICCC ($4.77) is undervalued by 7.73% relative to our estimate of its Fair Value price of $5.17 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ICCC ($4.77) is not significantly undervalued (7.73%) relative to our estimate of its Fair Value price of $5.17 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ICCC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ICCC due diligence checks available for Premium users.

Be the first to know about important ICCC news, forecast changes, insider trades & much more!

ICCC News

Valuation

ICCC fair value

Fair Value of ICCC stock based on Discounted Cash Flow (DCF)
Price
$4.77
Fair Value
$5.17
Undervalued by
7.73%
ICCC ($4.77) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ICCC ($4.77) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ICCC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ICCC price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-7.01x
Industry
11.81x
Market
54.01x

ICCC price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.31x
Industry
5.14x
ICCC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ICCC's financial health

Profit margin

Revenue
$3.4M
Net Income
-$2.3M
Profit Margin
-67.2%
ICCC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ICCC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$43.1M
Liabilities
$15.0M
Debt to equity
0.53
ICCC's short-term assets ($12.25M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ICCC's short-term assets ($12.25M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ICCC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ICCC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.8M
Investing
-$682.2k
Financing
$748.6k
ICCC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ICCC vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ICCC$36.95M-5.73%-7.01x1.31x
EVAX$36.69M-2.56%-1.55x4.42x
HEPA$36.59M-10.20%-0.71x0.98x
CASI$37.62M+1.44%-1.00x0.95x
ACXP$36.18M+8.01%-2.79x6.81x

Immucell Stock FAQ

What is Immucell's quote symbol?

(NASDAQ: ICCC) Immucell trades on the NASDAQ under the ticker symbol ICCC. Immucell stock quotes can also be displayed as NASDAQ: ICCC.

If you're new to stock investing, here's how to buy Immucell stock.

What is the 52 week high and low for Immucell (NASDAQ: ICCC)?

(NASDAQ: ICCC) Immucell's 52-week high was $9.61, and its 52-week low was $4.26. It is currently -50.34% from its 52-week high and 11.97% from its 52-week low.

How much is Immucell stock worth today?

(NASDAQ: ICCC) Immucell currently has 7,746,864 outstanding shares. With Immucell stock trading at $4.77 per share, the total value of Immucell stock (market capitalization) is $36.95M.

Immucell stock was originally listed at a price of $2.47 in Dec 31, 1997. If you had invested in Immucell stock at $2.47, your return over the last 25 years would have been 93.2%, for an annualized return of 2.67% (not including any dividends or dividend reinvestments).

How much is Immucell's stock price per share?

(NASDAQ: ICCC) Immucell stock price per share is $4.77 today (as of May 31, 2023).

What is Immucell's Market Cap?

(NASDAQ: ICCC) Immucell's market cap is $36.95M, as of Jun 1, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Immucell's market cap is calculated by multiplying ICCC's current stock price of $4.77 by ICCC's total outstanding shares of 7,746,864.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.